Since the identification of the causative gene, proprotein convertase subtilisin-kexin type 9 (PCSK9), in familial hypercholesterolemia family lines in 2003, the development of PCSK9-targeted inhibitors has progressed rapidly (42, 43). This evidence concerns the gene PCSK9 and familial hypercholesterolemia.